{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:44:30Z","timestamp":1790729070208,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interleukin-23 (IL-23) inhibitors and the IL-12\/23 inhibitor ustekinumab constitute a pivotal class of therapeutic agents employed in the clinical management of Psoriasis, a chronic immune-mediated skin disorder. Notwithstanding their therapeutic efficacy, concerns have arisen due to the emergence of multiple adverse events (AEs) associated with their usage. This study aims to provide a comprehensive examination of the distribution and characteristics of these AEs concerning IL-23 and IL-12\/23 inhibitors, with a specific focus on guselkumab, tildrakizumab, risankizumab, and ustekinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this research endeavor, we conducted an extensive analysis of data extracted from the FDA Adverse Event Reporting System (FAERS), spanning the timeframe from January 1, 2014, to September 30, 2022. To identify potential signals of AEs, we rigorously applied disproportionality analysis, utilizing both reporting odds ratio (ROR) and information component (IC) metrics. A signal was considered present when the lower limit of the 95% confidence interval (CI) for ROR (ROR025) exceeded one or when IC (IC025) surpassed zero, with a minimum requirement of three or more reported cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our investigation encompassed a substantial dataset, comprising a total of 41,408,408 reports detailing drug-AE associations and involving 13,271,168 individuals. Among these, 704, 13,164, and 11,399 patients were identified as users of the IL-23 inhibitors tildrakizumab, guselkumab, and risankizumab, respectively, while 62,853 patients were identified as users of the IL-12\/23 inhibitor ustekinumab. The analysis revealed the presence of 8, 20, 107, and 115 signals for these respective drugs. Significantly, the System Organ Class (SOC) exhibiting the highest incidence was \u201cinfections and infestations,\u201d with documented occurrences in tildrakizumab (6\/8), guselkumab (5\/20), ustekinumab (50\/107), and risankizumab (25\/115).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our pharmacovigilance analysis has brought to light a substantial frequency of AEs linked to IL-23 and IL-12\/23 inhibitors. These findings underscore the pivotal role of IL-23 and IL-12\/23 inhibitors in modulating immune function and raise concerns regarding their potential to heighten susceptibility to infections and malignancies. However, limitations inherent to the FAERS database, including underreporting, lack of denominator data, potential duplicate records, and inability to confirm causality, should be acknowledged of particular significance is risankizumab, which, despite having fewer reported cases and a later market introduction compared to ustekinumab, exhibited a higher incidence of AEs. These results emphasize the necessity for ongoing vigilance, further investigation, and a reevaluation of the safety profile of IL-23 and IL-12\/23 inhibitors in the clinical management of Psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-025-00837-y","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:00:04Z","timestamp":1737378004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Adverse events associated with IL-23 and IL-12\/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Wentao","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"9","key":"837_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"837_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Ann Rev Immunol. 2014;32(1):227\u201355.","journal-title":"Ann Rev Immunol"},{"key":"837_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Yi C, Blumenschein WM, Mattson J, Cua DJ, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233\u201340.","journal-title":"J Exp Med"},{"issue":"6","key":"837_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/ni.1613","volume":"9","author":"E Volpe","year":"2008","unstructured":"Volpe E, Servant N, Zollinger RL, Bogiatzi SI, Hup\u00e9 P, Barillot E, Soumelis V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9(6):650\u201357.","journal-title":"Nat Immunol"},{"issue":"2","key":"837_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ddmec.2005.05.019","volume":"2","author":"M Sticherling","year":"2006","unstructured":"Sticherling M. Mechanisms of psoriasis. Drug Discov Today Dis Mech. 2006;2(2):275\u201381.","journal-title":"Drug Discov Today Dis Mech"},{"issue":"6","key":"837_CR6","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM. Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359.","journal-title":"Br J Dermatol"},{"issue":"10148","key":"837_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Bruce S, Mark L, Matthias A, Andrew B, Yves P, Papp KA, Howard S, Llu\u00eds P, Peter F. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet (London, England). 2018;392(10148):650\u201361.","journal-title":"Lancet (London, England)"},{"key":"837_CR8","doi-asserted-by":"crossref","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, Nograles K, Mehta A, Cichanowitz N, Li Q. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017:276\u201388.","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"837_CR9","volume-title":"Comprehensive Dermatologic Drug Therapy","author":"EB Lee","year":"2021","unstructured":"Lee EB, Amin M, Wu JJ. Interleukin 23 inhibitors. In: Comprehensive Dermatologic Drug Therapy. Fourth ed.. 2021.","edition":"Fourth ed."},{"issue":"8","key":"837_CR10","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1111\/bcp.15581","volume":"89","author":"RH Woods","year":"2023","unstructured":"Woods RH. Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS). Br J Clin Pharmacol. 2023;89(8):2386\u201395.","journal-title":"Br J Clin Pharmacol"},{"key":"837_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"837_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","volume":"15","author":"PS Ang","year":"2016","unstructured":"Ang PS, Chen Z, Chan CL, Tai BC. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016;15(5):583\u201390.","journal-title":"Expert Opin Drug Saf"},{"key":"837_CR13","unstructured":"Yongfang H, Xiaofei Y, Guizhi W, Gang C, Xiaoxi D. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Expert Opin Drug Saf 2014."},{"issue":"1","key":"837_CR14","first-page":"57","volume":"22","author":"N Niklas","year":"2011","unstructured":"Niklas N, Johan H, Andrew B. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2011;22(1):57\u201369.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"837_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40257-013-0053-5","volume":"15","author":"AL Semble","year":"2014","unstructured":"Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-\u03b1 inhibitors in psoriasis: a narrative review. Am J Clin Dermatol. 2014;15(1):37\u201343.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"837_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14740338.2019.1614561","volume":"18","author":"SS Kolli","year":"2019","unstructured":"Kolli SS, Kepley AL, Cline A, Feldman SR. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data. Expert Opin Drug Saf. 2019;18(6):523\u201336.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"837_CR17","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.17624","volume":"180","author":"A Al-Janabi","year":"2019","unstructured":"Al-Janabi A, Jabbar-Lopez ZK, Griffiths C, Yiu Z. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. Br J Dermatol. 2019;180(6):1348\u201351.","journal-title":"Br J Dermatol"},{"issue":"16","key":"837_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Padula SJ. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","journal-title":"N Engl J Med"},{"issue":"3","key":"837_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","volume":"85","author":"NH Shear","year":"2021","unstructured":"Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021;85(3):572\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"837_CR20","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U","volume":"86","author":"JR Howe","year":"1999","unstructured":"Howe JR, Karnell LH, Menck HR, Scott-Conner C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer. 1999;86(12):2693\u2013706.","journal-title":"Cancer"},{"key":"837_CR21","volume-title":"Adverse Reactions to Biologics","author":"P Llu\u00eds","year":"2017","unstructured":"Llu\u00eds P. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. In: Adverse Reactions to Biologics. 2017."},{"issue":"211","key":"837_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/00012995-200112000-00001","volume":"1","author":"CJ Davies","year":"2001","unstructured":"Davies CJ, Davies DM. Paradoxical reactions to commonly used drugs. Adverse Drug React Bull. 2001;1(211):807\u201310.","journal-title":"Adverse Drug React Bull"},{"issue":"6","key":"837_CR23","first-page":"586","volume":"152","author":"E Oussedik","year":"2017","unstructured":"Oussedik E, Patel NU, Cash DR, Gupta AS, Feldman SR. The severe and acute complications of the biologics in psoriasis. G Ital Dermatol Venereol. 2017;152(6):586\u201396.","journal-title":"G Ital Dermatol Venereol"},{"key":"837_CR24","doi-asserted-by":"crossref","unstructured":"Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermo Sifiliogr\u00e1ficas. 2018;109(9):791\u2013800.","DOI":"10.1016\/j.adengl.2018.09.012"},{"key":"837_CR25","doi-asserted-by":"crossref","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman D. A Systematic review and meta-analysis of the efficacy and safety of the Interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatological Treat. 2018;1\u201337.","DOI":"10.1080\/09546634.2017.1422591"},{"key":"837_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, et al. Drug survival of Interleukin (IL)\u201117 and IL\u201123 inhibitors for the treatment of psoriasis: a retrospective multi\u2011country, multicentric cohort study. Am J Clin Dermatol 2022;23:891\u2013904.","journal-title":"Am J Clin Dermatol"},{"key":"837_CR27","doi-asserted-by":"publisher","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","volume":"14","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, et al Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis). Front Immunol. 2023;14:1341708.","journal-title":"Front Immunol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00837-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00837-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00837-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:00:08Z","timestamp":1737378008000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00837-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00837-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3510599\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical guidelines"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}